James Lewis, MD, MSCE
|Office Location||720, Blockley Hall|
|Office Phone||(215) 573-5137|
|CCEB Appointment||Senior Scholar, Epidemiology|
|Primary Faculty Appointment||Professor of Medicine, Gastroenterology Division, University of Pennsylvania SOM|
|DBE Appointment||Professor of Epidemiology|
Senior Fellow, Leonard Davis Institute
Associate Director, Inflammatory Bowel Disease Program
Dr. James Lewis earned a BA in Interdisciplinary Studies from the University of Virginia in 1987. He received his MD degree from the University of Pennsylvania in 1991. He completed a residency in Internal Medicine and subsequently served as Chief Medical Resident at Yale University. Following his residency, Dr. Lewis simultaneously completed a fellowship in Gastroenterology and obtained a masterís degree in Clinical Epidemiology at the University of Pennsylvania. He joined the faculty at the University of Pennsylvania in 1998 and currently is Professor of Medicine and Epidemiology, Senior Scholar at the Center for Clinical Epidemiology and Biostatistics, Senior Fellow in the Leonard Davis Institute of Health Economics, Associate Director of the Penn Inflammatory Bowel Disease Program, and Director of the Gastroenterology and Hepatology Clinical Research Program.
Dr. Lewis has been actively involved in research related to inflammatory bowel disease since 1996 and has published more than 200 scholarly articles. His research covers a broad range of topics, but primarily focuses on issues related to medication safety and optimizing medical therapies. Examples include a series of studies investigating whether patients treated with various medications for IBD are at increased risk for cancer, infections, neurologic diseases, and death, and whether such risks are warranted given the effectiveness of the therapy. Dr. Lewis is one of limited number of investigators to lead NIH funded clinical trials of novel therapeutic strategies for IBD. He has directed two clinical trials of rosiglitazone to treat ulcerative colitis and a trial of using biomarkers to adjust medical therapy for ulcerative colitis. He is currently on the steering committee of an NIH funded trial examining the efficacy of methotrexate for ulcerative colitis. In recent years, Dr. Lewis and his colleagues have begun to focus their research on how diet and the microorganisms that inhabit the human intestine may influence the course of IBD. Dr. Lewis hopes that this research may help to identify novel strategies for treating IBD that are not based on systemic immunosuppression.
EP 510 - Introductory Epidemiology
Lewis JD, Asch DA.: Barriers to office-based screening sigmoidoscopy: does reimbursement cover costs? Annals of Internal Medicine. 130: 525-30 (1999).
Lewis JD, Brown A, Schwartz JS.: Initial evaluation of rectal bleeding in young persons: A cost-effectiveness analysis. Annals of Internal Medicine. 136: 99-110 (2002).
Yang YX, Lewis JD, Epstein S, Metz DC. Chronic proton pump inhibitor therapy and hip fracture risk. JAMA. 296:2947-53 (2006).
Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology.118: 1018-24 (2000).
Lewis JD (3), Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 121:1080-7 (2001).
Kandiel A, Fraser AJ, Korelitz BI, Brensinger C, Lewis JD. Increased Risk of Lymphoma among Inflammatory Bowel Disease Patients Treated with Azathioprine and 6-Mercaptopurine. Gut. 54:1121-5 (2005).
Gupta G, Gelfand JM, Lewis JD. Increased risk of demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology. 129:819-26 (2005).
Lewis JD, Gelfand JM, Troxel AB, Forde KA, Newcomb C, Kim H, Margolis DJ, Strom BL: Immunosuppression medications and mortality in inflammatory bowel disease. American Journal of Gastroenterology. 103: 1428-35 (2008).
Lewis JD, Lichtenstein GR, Deren JJ, Sands BE, Hanauer SB, Katz JA, Lashner B, Present DH, Chuai S, Ellenberg JE, Nessel L, Wu GD. Rosiglitazone for ulcerative colitis: a placebo-controlled trial. Gastroenterology. 134:688-95 (2008).
Lewis JD, Capra AM, Achacoso NS, Ferrara A, Levin TR, Quesenberry CP Jr., Habel LA: Thiazolidinedione Therapy Is Not Associated with Increased Colonic Neoplasia Risk in Patients with Diabetes Mellitus. Gastroenterology. 135: 1914-23 (2008).